Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: GlobeNewswire
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating that Sangamo’s common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq’s minimum bid price requirement. Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination. The hearing will not stay the suspension of trading of Sangamo’s common stock, and trading of Sangamo’s common stock on The Nasdaq Capital Market is expected to be suspended at the open of trading on May 5, 2026. Sangamo has secured approval for its common stock to be quoted on the OTCQB Venture Market, operated by OTC Markets Group. Sangamo expects its common stock to begin trading on
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics (SGMO) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- ???????????2035????702.2???????????????(CAGR)22.78%??? [CNET News]CNET News
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
SGMO
Earnings
- 3/30/26 - Miss
SGMO
Analyst Actions
- 2/10/26 - HC Wainwright
SGMO
Sec Filings
- 4/29/26 - Form 8-K
- 4/23/26 - Form 4
- 4/23/26 - Form 4
- SGMO's page on the SEC website